|
1
|
Ferlay J, Soerjomataram I, Ervik M, et al:
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC
CancerBase No. 11. International Agency for Research on Cancer;
Lyon: 2013 Last accessed April, 2014
|
|
2
|
Weigel MT and Dowsett M: Current and
emerging biomarkers in breast cancer: prognosis and prediction.
Endocr Relat Cancer. 17:R245–R262. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu M, Stott S, Toner M, Maheswaran S and
Haber DA: Circulating tumor cells: approaches to isolation and
characterization. J Cell Biol. 192:373–382. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wallwiener M, Hartkopf AD, Baccelli I, et
al: The prognostic impact of circulating tumor cells in subtypes of
metastatic breast cancer. Breast Cancer Res Treat. 137:503–510.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hayes DF, Cristofanilli M, Budd GT, et al:
Circulating tumor cells at each follow-up time point during therapy
of metastatic breast cancer patients predict progression-free and
overall survival. Clin Cancer Res. 12:4218–4224. 2006. View Article : Google Scholar
|
|
6
|
Cristofanilli M, Budd GT, Ellis MJ, et al:
Circulating tumor cells, disease progression, and survival in
metastatic breast cancer. N Engl J Med. 351:781–791. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu Y, Liu Q, Wang T, et al: Circulating
tumor cells in HER2-positive metastatic breast cancer patients: a
valuable prognostic and predictive biomarker. BMC Cancer.
13:2022013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang ZF, Cristofanilli M, Shao ZM, et al:
Circulating tumor cells predict progression-free and overall
survival in Chinese patients with metastatic breast cancer,
HER2-positive or triple-negative (CBCSG004): a multicenter,
double-blind, prospective trial. Ann Oncol. 24:2766–2772. 2013.
View Article : Google Scholar
|
|
9
|
Yusa A, Toneri M, Masuda T, et al:
Development of a new rapid isolation device for circulating tumor
cells (CTCs) using 3D palladium filter and its application for
genetic analysis. PLoS One. 9:e888212014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu S, Liu Z, Liu S, Lin L, Yang W and Xu
J: Enrichment and enumeration of circulating tumor cells by
efficient depletion of leukocyte fractions. Clin Chem Lab Med.
52:243–251. 2014.PubMed/NCBI
|
|
11
|
Zhao M, Schiro PG, Kuo JS, et al: An
automated high-throughput counting method for screening circulating
tumor cells in peripheral blood. Anal Chem. 85:2465–2471. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee HJ, Cho HY, Oh JH, et al: Simultaneous
capture and in situ analysis of circulating tumor cells using
multiple hybrid nanoparticles. Biosens Bioelectron. 47:508–514.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nagrath S, Sequist LV, Maheswaran S, et
al: Isolation of rare circulating tumour cells in cancer patients
by microchip technology. Nature. 450:1235–1239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Krishnamurthy S, Cristofanilli M, Singh B,
et al: Detection of minimal residual disease in blood and bone
marrow in early stage breast cancer. Cancer. 116:3330–3337. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu C, Hao H, Li L, et al: Preliminary
investigation of the clinical significance of detecting circulating
tumor cells enriched from lung cancer patients. J Thorac Oncol.
4:30–36. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gorges TM, Tinhofer I, Drosch M, et al:
Circulating tumour cells escape from EpCAM-based detection due to
epithelial-to-mesenchymal transition. BMC Cancer. 12:1782012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Armstrong AJ, Marengo MS, Oltean S, et al:
Circulating tumor cells from patients with advanced prostate and
breast cancer display both epithelial and mesenchymal markers. Mol
Cancer Res. 9:997–1007. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu M, Bardia A, Wittner BS, et al:
Circulating breast tumor cells exhibit dynamic changes in
epithelial and mesenchymal composition. Science. 339:580–584. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Z, Fusi A, Klopocki E, et al: Negative
enrichment by immunomagnetic nanobeads for unbiased
characterization of circulating tumor cells from peripheral blood
of cancer patients. J Transl Med. 9:702011. View Article : Google Scholar
|
|
20
|
Hyun KA, Lee TY and Jung HI: Negative
enrichment of circulating tumor cells using a geometrically
activated surface interaction chip. Anal Chem. 85:4439–4445. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sajay BN, Chang CP, Ahmad H, et al:
Microfluidic platform for negative enrichment of circulating tumor
cells. Biomed Microdevices. 6:537–548. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang L, Lang JC, Balasubramanian P, et al:
Optimization of an enrichment process for circulating tumor cells
from the blood of head and neck cancer patients through depletion
of normal cells. Biotechnol Bioeng. 102:521–534. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lara O, Tong X, Zborowski M and Chalmers
JJ: Enrichment of rare cancer cells through depletion of normal
cells using density and flow-through, immunomagnetic cell
separation. Exp Hematol. 32:891–904. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tong X, Yang L, Lang JC, Zborowski M and
Chalmers JJ: Application of immunomagnetic cell enrichment in
combination with RT-PCR for the detection of rare circulating head
and neck tumor cells in human peripheral blood. Cytometry B Clin
Cytom. 72:310–323. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stathopoulou A, Gizi A, Perraki M, et al:
Real-time quantification of CK-19 mRNA-positive cells in peripheral
blood of breast cancer patients using the lightcycler system. Clin
Cancer Res. 9:5145–5151. 2003.PubMed/NCBI
|
|
26
|
Ntoulia M, Stathopoulou A, Ignatiadis M,
et al: Detection of Mammaglobin A-mRNA-positive circulating tumor
cells in peripheral blood of patients with operable breast cancer
with nested RT-PCR. Clin Biochem. 39:879–887. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ignatiadis M, Kallergi G, Ntoulia M, et
al: Prognostic value of the molecular detection of circulating
tumor cells using a multimarker reverse transcription-PCR assay for
cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.
Clin Cancer Res. 14:2593–2600. 2008. View Article : Google Scholar
|
|
28
|
de Cremoux P, Extra JM, Denis MG, et al:
Detection of MUC1-expressing mammary carcinoma cells in the
peripheral blood of breast cancer patients by real-time polymerase
chain reaction. Clin Cancer Res. 6:3117–3122. 2000.PubMed/NCBI
|
|
29
|
Varangot M, Barrios E, Sonora C, et al:
Clinical evaluation of a panel of mRNA markers in the detection of
disseminated tumor cells in patients with operable breast cancer.
Oncol Rep. 14:537–545. 2005.PubMed/NCBI
|
|
30
|
Reinholz MM, Nibbe A, Jonart LM, et al:
Evaluation of a panel of tumor markers for molecular detection of
circulating cancer cells in women with suspected breast cancer.
Clin Cancer Res. 11:3722–3732. 2005. View Article : Google Scholar : PubMed/NCBI
|
